New hope for advanced cancer: experimental drug targets HER2

NCT ID NCT06512116

Recruiting now Disease control Sponsor: Shanghai Institute Of Biological Products Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER2 found on some cancer cells. The study aims to find the safest dose and understand how the drug works in the body. About 196 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIBP-A17 (a drug that targets HER2 protein on cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial, so the drug may not be effective or may have serious side effects. The results are preliminary and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female reproductive organ cancer HER2 positive breast carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.